The DOI matches its Crossref record.
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Abstract
Using specific radioimmunoassays, we studied the occurrence of amidated and glycine-extended glucagon-like peptide I (GLP-I) molecules in the human small intestine and pancreas and in the circulation system in response to a breakfast meal. Through gel permeation chromatography of extracts of the human pancreas (n = 5), we found that 71% of the GLP-I immunoreactivity eluted as a large molecule corresponding to the major proglucagon fragment, 24% corresponded to GLP-I 1–36 amide, and 5% to GLP-I 1–37. By gel permeation chromatography of extracts of human small intestine (n = 6), we found that all immunoreactivity eluted in one peak at the common elution position of the two insulin-releasing peptides, GLP-I 7–36 amide and GLP-I 7–37. Of the GLP-I immunoreactivity, 80% corresponded to GLP-I 7–36 amide and 20% to GLP-I 7–37. The mean concentrations of amidated GLP-I and glycine-extended GLP-I in fasting plasma were 7 ± 1 and 6 ± 1 pM, respectively (n = 6). In response to a breakfast meal, the concentration of amidated GLP-I rose significantly amounting to 41 ± 5 pM 90 min after the meal ingestion, whereas the concentration of glycine-extended GLP-I only rose slightly to a maximum of 10 ± 1 pM. Thus, both amidated and glycine-extended GLP-I molecules are produced in the small intestine and in the pancreas in humans. Both amidated and glycine-extended GLP-I are measurable in fasting plasma. The higher meal response of amidated GLP-I compared with glycine-extended GLP-I probably reflects the larger amount of amidated GLP-I produced in the tissues compared with glycine-extended GLP-I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988
Self-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 601
Patti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity · doi:10.1038/oby.2009.102 · Cited by 591
“Plasma GLP-1 was measured after extraction of serum with 70% ethanol (vol/vol) (15), using antiserum (code 89390) specific for the amidated C-terminus of GLP-1 and therefore primarily reactive with GLP-1 of intestinal origin.”
MethodHansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Self-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Self-citationThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Gut microbiota, obesity and diabetes
Patterson, E., Ryan, P. M., Cryan, J. F., Dinan, T. G., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133285 · Cited by 552
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
“C-terminal GLP-1 (total) immunoreactivity was measured as described previously ( 19 ), using standards of synthetic GLP-1(7–36)amide ( proglucagon 78 –107amide) and antiserum no. 89390.”
MethodSelf-citationFEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citationNilsson, M., Stenberg, M., Frid, A. H., Holst, J. J., & Björck, I. M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.5.1246 · Cited by 473
Self-citationEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Self-citationSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
“Typically, ‘total’ GLP-1 concentrations are between 5 and 15 pmol/l in the basal state, rising to between 20 and 60 pmol/l after oral glucose or meals [12, 16, 21].”
BackgroundSelf-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Self-citationVerdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Self-citationMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
Self-citationChristiansen, C. B., Gabe, M. B. N., Svendsen, B., Dragsted, L. O., Rosenkilde, M. M., & Holst, J. J. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00346.2017 · Cited by 401
Self-citationHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396
Frid, A. H., Nilsson, M., Holst, J. J., & Björck, I. (2005) · American Journal of Clinical Nutrition · doi:10.1093/ajcn.82.1.69 · Cited by 388
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
“determined in ethanol-extracted plasma as previously described (15,18), using antiserum 89 390 for the measurement of intact GLP-1 [7–36 amide] plus cleavage products.”
MethodSelf-citationFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
Self-citationGoldfine, A. B., Mun, E. C., Devine, E., Bernier, R., Baz-Hecht, M., Jones, D. B., Schneider, B. E., Holst, J. J., & Patti, M. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0918 · Cited by 377
“89390, specific for the amidated C terminus of GLP-1 and, therefore, equally reactive with intact GLP-1 and with GLP-1 3–36 amide, the primary metabolite (15).”
BackgroundSelf-citationAntihyperglycemic effects of stevioside in type 2 diabetic subjects
Gregersen, S., Jeppesen, P. B., Holst, J. J., & Hermansen, K. (2004) · Metabolism · doi:10.1016/j.metabol.2003.07.013 · Cited by 375
Self-citationNilsson, M., Holst, J. J., & Björck, I. M. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.4.996 · Cited by 374
Self-citationGut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373
“GLP-1 is released post-prandially into the circulation from the gastrointestinal L cells in proportion to the calories ingested.(50,51) It has been shown that GLP-1 shows a biphasic response after a meal.”
BackgroundMeier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Self-citationReduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Self-citationZhu, X., Zhou, A., Dey, A., Norrbom, C., Carroll, R., Zhang, C., Laurent, V., Lindberg, I., Ugleholdt, R., Holst, J. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162352599 · Cited by 348
Self-citationGastrointestinal hormones regulating appetite
Chaudhri, O., Small, C., & Bloom, S. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 346
Jacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Self-citationKorner, J., Bessler, M., Inabnet, W., Taveras, C., & Holst, J. J. (2007) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2007.08.004 · Cited by 344
Self-citationGastrointestinal Satiety Signals
Chaudhri, O. B., Salem, V., Murphy, K. G., & Bloom, S. R. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100506 · Cited by 334
Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption
Henriksen, D. B., Alexandersen, P., Bjarnason, N. H., Vilsbøll, T., Hartmann, B., Henriksen, E. E., Byrjalsen, I., Krarup, T., Holst, J. J., & Christiansen, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2180 · Cited by 332
Self-citationCanfora, E. E., van der Beek, C. M., Jocken, J. W. E., Goossens, G. H., Holst, J. J., Olde Damink, S. W. M., Lenaerts, K., Dejong, C. H. C., & Blaak, E. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-02546-x · Cited by 331
Self-citationFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Müller, M., Hernández, M. A. G., Goossens, G. H., Reijnders, D., Holst, J. J., Jocken, J. W. E., van Eijk, H., Canfora, E. E., & Blaak, E. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-48775-0 · Cited by 324
Self-citationThe role of gut hormones and the hypothalamus in appetite regulation
Suzuki, K., Simpson, K. A., Minnion, J. S., Shillito, J. C., & Bloom, S. R. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-077 · Cited by 319
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“TheGLP-1(1–37) precursor peptide is truncated to the active sequence, GLP-1(7–37), and this in turn can be amidated to form GLP-1(7–36) amide, which is the major active circulating form of GLP-1 [6].”
BackgroundInfluentialFalkén, Y., Hellström, P. M., Holst, J. J., & Näslund, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2876 · Cited by 315
Self-citationJørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Ghrelin stimulates gastric emptying and hunger in normal-weight humans
Levin, F., Edholm, T., Schmidt, P. T., Grybäck, P., Jacobsson, H., Degerblad, M., Höybye, C., Holst, J. J., Rehfeld, J. F., Hellström, P. M., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2638 · Cited by 313
Self-citationHansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
Self-citationDeacon, C. F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O., & Holst, J. J. (1998) · Diabetologia · doi:10.1007/s001250050903 · Cited by 303
Self-citationPostprandial glucose, insulin, and incretin responses to grain products in healthy subjects
Juntunen, K. S., Niskanen, L. K., Liukkonen, K. H., Poutanen, K. S., Holst, J. J., & Mykkänen, H. M. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.2.254 · Cited by 300
Self-citationMannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300
Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.3.e458 · Cited by 299
Self-citation2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans
Hansen, K. B., Rosenkilde, M. M., Knop, F. K., Wellner, N., Diep, T. A., Rehfeld, J. F., Andersen, U. B., Holst, J. J., & Hansen, H. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0647 · Cited by 297
Self-citationAhrén, B., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1030 · Cited by 292
Self-citationNauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Strader, A. D., Vahl, T. P., Jandacek, R. J., Woods, S. C., D’Alessio, D. A., & Seeley, R. J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2004 · Cited by 291
Calbet, J. A. L., & Holst, J. J. (2004) · European Journal of Nutrition · doi:10.1007/s00394-004-0448-4 · Cited by 288
Self-citationJørgensen, N. B., Dirksen, C., Bojsen-Møller, K. N., Jacobsen, S. H., Worm, D., Hansen, D. L., Kristiansen, V. B., Naver, L., Madsbad, S., & Holst, J. J. (2013) · Diabetes · doi:10.2337/db13-0022 · Cited by 288
Self-citationEffects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 285
Self-citationGLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Näslund, E., Bogefors, J., Skogar, S., Grybäck, P., Jacobsson, H., Holst, J. J., & Hellström, P. M. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r910 · Cited by 284
Self-citationDirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Jacobsen, S. H., Clausen, T. R., Worm, D., Hartmann, B., Rehfeld, J. F., Damgaard, M., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.15 · Cited by 276
Self-citationHare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Self-citationAntihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 273
Ørskov, C., Wettergren, A., & Holst, J. J. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609009147 · Cited by 271
Self-citationHolst, J. J. (1997) · Annual Review of Physiology · doi:10.1146/annurev.physiol.59.1.257 · Cited by 267
Self-citationGreenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood, A., Reimann, F., Holst, J. J., & Gribble, F. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26362 · Cited by 256
Self-citationGlucagonlike peptide 1: a newly discovered gastrointestinal hormone
Holst, J. J. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90831-1 · Cited by 252
Self-citationSimon, M.-C., Strassburger, K., Nowotny, B., Kolb, H., Nowotny, P., Burkart, V., Zivehe, F., Hwang, J.-H., Stehle, P., Pacini, G., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2690 · Cited by 253
Self-citationThe Effects of Exercise-Induced Weight Loss on Appetite-Related Peptides and Motivation to Eat
Martins, C., Kulseng, B., King, N. A., Holst, J. J., & Blundell, J. E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2082 · Cited by 236
Self-citationvan der Beek, C. M., Canfora, E. E., Lenaerts, K., Troost, F. J., Olde Damink, S. W. M., Holst, J. J., Masclee, A. A. M., Dejong, C. H. C., & Blaak, E. E. (2016) · Clinical Science · doi:10.1042/cs20160263 · Cited by 230
Self-citationSkov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228
Self-citationImpaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“GLP-1 in the circulation is rapidly increased by nutrients such as carbohydrates, fats, proteins, and dietary fiber and is truncated and amidated into two active forms: GLP-1 (7–37) and GLP-1 (7–36) amide [14].”
BackgroundFærch, K., Vistisen, D., Pacini, G., Torekov, S. S., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., et al. (2016) · Diabetes · doi:10.2337/db16-0240 · Cited by 217
Self-citationPrigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationImpact of cereal fibre on glucose-regulating factors
Weickert, M. O., Mohlig, M., Koebnick, C., Holst, J. J., Namsolleck, P., Ristow, M., Osterhoff, M., Rochlitz, H., Rudovich, N., Spranger, J., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1941-x · Cited by 194
Self-citationGasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Self-citationSvane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185
Self-citationDirksen, C., Damgaard, M., Bojsen‐Møller, K. N., Jørgensen, N. B., Kielgast, U., Jacobsen, S. H., Naver, L. S., Worm, D., Holst, J. J., Madsbad, S., et al. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12087 · Cited by 184
McLaughlin, T., Peck, M., Holst, J., & Deacon, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1628 · Cited by 183
Self-citationA Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
Edholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164
Self-citationGastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7743 · Cited by 164
Self-citationWettergren, A., Wøjdemann, M., Meisner, S., Stadil, F., & Holst, J. J. (1997) · Gut · doi:10.1136/gut.40.5.597 · Cited by 153
Self-citation
Metadata
- Authors
- Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1994-04-01
- Volume
- 43
- Issue
- 4
- Pages
- 535-539
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2166073051
- Cited by
- 919
- References
- 0
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.